Bio-Gate AG signs LOI for trauma implants with North American medical device manufacturer
Nuremberg/Bremen, July 31, 2023 – Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative technologies and individual solutions for health and hygiene, has signed a preliminary agreement (LOI, letter-of -Intent) completed. The medical device manufacturer intends to use Bio-Gate’s “HyProtect” coating process for its own implants in human medicine after the FDA approval process.
With the North American manufacturer of medical products, Bio-Gate has gained another important company as a partner for its “HyProtect” coating technology and can open up significant growth potential in applications for human medicine. The company sees the repeatedly documented interest of leading suppliers from the medical technology industry in Bio-Gate’s HyProtect coating as strong evidence of the high relevance of the technology.
Bio-Gate uses “HyProtect” technology to coat medical devices with an ultra-thin layer containing polysiloxane and silver. The release of silver ions ensures an antibacterial effect without changing the product properties, such as biocompatibility or biomechanical behavior. The infection data on the previous use of “HyProtect” are very positive, especially for implants in individual care in human medicine and also serially in veterinary medicine.
Financial calendar 2023
Beginning of September: Half-Year Group Report as of June 30, 2023
15./16. November: MKK Munich
Investor Relations
Bio-Gate AG / Gerd Rückel
Neumeyerstr. 28-34
D-90411 Nuremberg
Tel. +49 (0) 911 477523-444
Mobil +49 (0)152 34221966
Presse
Bio-Gate AG
Neumeyerstr. 28-34
D-90411 Nuremberg
Tel. +49 (0) 911 477523-222
About Bio Gate AG
The health technology company Bio-Gate AG is a leading provider of innovative technologies and products for health, infection control and hygiene that can make living together safer, more carefree and healthier and improve the well-being of every individual. It specializes in equipping materials and surfaces with antiviral, antimicrobial or biologically active properties. Bio-Gate AG refines materials and products, especially from medical technology, such as the coating of implants or wound dressings. In addition, dermatological active cosmetics and wound care products as well as consumer and industrial products are made antiviral, antimicrobial or biologically effective with the Bio-Gate technologies and are thus upgraded in a unique way.
Disclaimer
This publication is neither an offer to sell nor a solicitation to buy any securities. The shares of Bio-Gate AG (the “Shares”) may not be registered in the United States or “US persons” (as defined in Regulation S of the United States Securities Act of 1933, as amended (the “Securities Act”) ) or offered or sold for the account of US persons. The securities have already been sold.
The health technology company Bio-Gate AG is a leading provider of innovative technologies and products for health, infection control and hygiene that can make living together safer, more carefree and healthier and improve the well-being of every individual. It specializes in equipping materials and surfaces with antiviral, antimicrobial or biologically active properties. Bio-Gate AG refines materials and products, especially from medical technology, such as the coating of implants or wound dressings. In addition, dermatological active cosmetics and wound care products as well as consumer and industrial products are made antiviral, antimicrobial or biologically effective with the Bio-Gate technologies and are thus upgraded in a unique way.
Contact
Bio-Gate
Gerd Rueckel
Neumeyerstraße 28-34
90411 Nuremberg
015234221966